The next wave of cellular immunotherapies in pancreatic cancer

Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around 10%. Pancreatic cancer typically presents late with locally advanced or metastatic disease, and there are limited effective treatments available. Cellular immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has had significant success in treating hematological malignancies. However, CAR T cell therapy efficacy in pancreatic cancer has been limited. This review provides an overview of current and ongoing CAR T cell clinical studies of pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy. These strategies include arming CAR T cells; developing off-the-shelf allogeneic CAR T cells; using other immune CAR cells, like natural killer cells and tumor-infiltrating lymphocytes; and combination therapy. Careful incorporation of preclinical models will enhance management of affected individuals, assisting incorporation of cellular immunotherapies. A multifaceted, personalized approach involving cellular immunotherapy treatment is required to improve pancreatic cancer outcomes.

• Publication year

  2022

• Venue

  Molecular Therapy: Oncolytics

• Publication date

  2022-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.omto.2022.01.010PMID 35229033PMCID 8857655
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.

  2021cited by this paper
• Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors

  2021cited by this paper
• Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy

  2021cited by this paper
• Allogeneic CAR Cell Therapy—More Than a Pipe Dream

  2021cited by this paper
• A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization

  2021cited by this paper
• Cancer Statistics, 2021

  2021cited by this paper
• CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma

  2021cited by this paper
• CAR NK Cell Therapy Directed Against Pancreatic Cancer

  2021influential reference
• Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro

  2021cited by this paper
• Anti-Mesothelin CAR T cell therapy for malignant mesothelioma

  2021cited by this paper
• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

  2021cited by this paper
• Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model

  2021cited by this paper
• CAR-NK Cells in the Treatment of Solid Tumors

  2021influential reference
• T cells armed with the C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

  2021cited by this paper
• ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

  2020cited by this paper
• Combination Therapy for Solid Tumors: Taking a Classic CAR on New Adventures.

  2020cited by this paper
• Human NK-92 Cells Function as Target Cells for Human NK Cells – Implications for CAR NK-92 Therapies

  2020cited by this paper
• Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant

  2020cited by this paper
• CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?

  2020cited by this paper
• Establishment of patient-derived cancer organoids for drug-screening applications

  2020cited by this paper
• Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

  2020cited by this paper
• Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.

  2020influential reference
• Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

  2020cited by this paper
• Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.

  2020influential reference
• Off-the-shelf ipsc derived car-nk immunotherapy for solid tumors

  2020influential reference
• Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis

  2020cited by this paper
• Toward “off‐the‐shelf” allogeneic CAR T cells

  2020cited by this paper
• KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

  2020cited by this paper
• T Cell Engineering and the Rise of CAR-T Cell Therapies

  2020cited by this paper
• Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma.

  2020cited by this paper
• Working together to reduce the burden of pancreatic cancer.

  2020cited by this paper
• Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.

  2020cited by this paper
• Interleukin-23 engineering improves CAR T cell function in solid tumors

  2020cited by this paper
• Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.

  2020cited by this paper
• Patient-derived xenograft models—the future of personalised cancer treatment

  2020cited by this paper
• Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects

  2020cited by this paper
• Abstract A014: Phase I clinical trial with PD-1/MUC1 CAR-pNK92 immunotherapy

  2019cited by this paper
• Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

  2019cited by this paper
• Pancreatic cancer: An update on diagnosis and management.

  2019cited by this paper
• Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2

  2019cited by this paper
• Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.

  2019cited by this paper
• Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

  2019influential reference
• Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of 125I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma

  2019cited by this paper
• Isolation of Tumor-Infiltrating Lymphocytes by Ficoll-Paque Density Gradient Centrifugation.

  2019cited by this paper
• 3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids

  2019cited by this paper
• Manufacturing chimeric antigen receptor T cells: issues and challenges.

  2019cited by this paper
• Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors

  2019cited by this paper
• Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.

  2019cited by this paper
• Organoid models for translational pancreatic cancer research.

  2019cited by this paper
• Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

  2019cited by this paper
• Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.

  2019cited by this paper
• Current challenges and emerging opportunities of CAR-T cell therapies.

  2019cited by this paper
• Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.

  2018cited by this paper
• Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.

  2018cited by this paper
• Preclinical Models in Chimeric Antigen Receptor–Engineered T-Cell Therapy

  2018influential reference
• The market for chimeric antigen receptor T cell therapies

  2018cited by this paper
• Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.

  2018cited by this paper
• Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy.

  2018cited by this paper
• Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

  2018cited by this paper
• Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

  2018cited by this paper
• Surgical treatment of pancreatic cancer.

  2018cited by this paper
• CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

  2018influential reference
• Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors

  2018cited by this paper
• Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.

  2018cited by this paper
• Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy

  2018cited by this paper
• Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma

  2018cited by this paper
• Patient‐derived organoid models help define personalized management of gastrointestinal cancer

  2018cited by this paper
• Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors

  2018cited by this paper
• The Potential of CAR T Cell Therapy in Pancreatic Cancer

  2018cited by this paper
• Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

  2018cited by this paper
• Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

  2018influential reference
• Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

  2018cited by this paper
• IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

  2018cited by this paper
• Pancreatic cancer subtypes: a roadmap for precision medicine

  2018influential reference
• Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors

  2017cited by this paper
• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  2017influential reference
• Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer

  2017cited by this paper
• CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity

  2017cited by this paper
• Therapeutic T cell engineering

  2017cited by this paper
• Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.

  2017cited by this paper
• A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects

  2017cited by this paper
• Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

  2017cited by this paper
• Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

  2017cited by this paper
• Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer.

  2017cited by this paper
• Humanized Mouse Models of Clinical Disease.

  2017cited by this paper
• CAR T-cells: an exciting frontier in cancer therapy.

  2017cited by this paper
• Prospects for combined use of oncolytic viruses and CAR T-cells

  2017cited by this paper
• Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy

  2017cited by this paper
• Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy

  2017cited by this paper
• Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

  2017cited by this paper
• Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers

  2017cited by this paper
• Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms

  2017cited by this paper
• Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

  2017cited by this paper
• CD133, Selectively Targeting the Root of Cancer

  2016cited by this paper
• Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma

  2016cited by this paper
• Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

  2016cited by this paper
• Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.

  2016cited by this paper
• Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery

  2016cited by this paper
• Systemic Chemotherapy in Advanced Pancreatic Cancer

  2016cited by this paper
• Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

  2016cited by this paper

• CAR-T/NK/M-based combination therapies in cancer: A comprehensive review.

  2026cites this paper
• Prognostic value of tumor-infiltrating lymphocytes, tumor associated neutrophils and metabolic checkpoint molecules on survival of patients with metastatic pancreatic ductal adenocarcinoma

  2025cites this paper
• Ibrutinib and PD-1 blockade potentiate mesothelin-targeting CAR-T cell therapy in preclinical models of pancreatic cancer.

  2025cites this paper
• Review of design strategies for active targeted drug delivery systems for pancreatic cancer.

  2025cites this paper
• High mesothelin expression is associated with low cytotoxic T cell infiltration in pancreatic cancer

  2025cites this paper
• The Possible Role of Immunotherapy in Locally Advanced Pancreatic Cancer Treatment

  2025influential citation
• Emerging Systemic Therapy Considerations for Pancreatic Cancer.

  2025cites this paper
• MS2 virus-like particles as a versatile platform for multi-disease vaccines: a review

  2025cites this paper
• Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions

  2025cites this paper
• Synergistic Anti-Tumor Efficacy of Modified FOLFIRINOX and NK Cell Therapy in Pancreatic Ductal Adenocarcinoma

  2025influential citation
• Harnessing the chimeric antigen receptor engineered cells in gastrointestinal cancer immunotherapy.

  2025cites this paper
• Bibliometric analysis of global research trends in pancreatic cancer immunotherapy

  2025cites this paper
• Exosome-mediated triple drug delivery enhances apoptosis in pancreatic cancer cells

  2025cites this paper
• Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation

  2025cites this paper
• Vascular Endothelial Growth Factor Receptors in the Vascularization of Pancreatic Tumors: Implications for Prognosis and Therapy

  2025cites this paper
• Revolutionizing pancreatic cancer treatment with CAR-T therapy.

  2025cites this paper
• A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8+ T cell fitness in solid tumours

  2025cites this paper
• Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer

  2024cites this paper
• Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence

  2024cites this paper
• The progress of optional targets and approaches to enhance efficacy of CAR-T for pancreatic ductal adenocarcinoma

  2024cites this paper
• An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer

  2024cites this paper
• Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome Treatment Resistance.

  2024cites this paper
• Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma

  2024cites this paper
• Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis.

  2024cites this paper
• Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma.

  2024cites this paper
• Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells

  2024cites this paper
• Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.

  2024cites this paper
• Carcinogenic effect of human tumor-derived cell-free filtrates in nude mice

  2024cites this paper
• Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Current and future immunotherapeutic approaches in pancreatic cancer treatment

  2024cites this paper
• The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review

  2024influential citation
• Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds.

  2024cites this paper
• Reprogramming tumor immune microenvironment by milbemycin oxime results in pancreatic tumor growth suppression and enhanced anti-PD1 efficacy.

  2024cites this paper
• Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma.

  2024cites this paper
• TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma

  2024cites this paper
• The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives

  2024cites this paper
• Identification of STAM-binding protein as a target for the treatment of gemcitabine resistance pancreatic cancer in a nutrient-poor microenvironment

  2024cites this paper
• Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy

  2024cites this paper
• Recent advances and progress in immunotherapy of solid cancers.

  2024cites this paper
• Modulation of PRC1 Promotes Anticancer Effects in Pancreatic Cancer

  2024cites this paper
• Identification of M2 macrophage-related genes for establishing a prognostic model in pancreatic cancer: FCGR3A as key gene

  2024cites this paper
• Advancing Immunotherapy in Pancreatic Cancer

  2024cites this paper
• The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances

  2024cites this paper
• Molecular mechanism of tumor microenvironment and recent approaches for the immunotherapy of pancreatic cancer

  2024cites this paper
• Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond

  2023cites this paper
• PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer

  2023cites this paper
• Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Determination and characterization of molecular heterogeneity and precision medicine strategies of patients with pancreatic cancer and pancreatic neuroendocrine tumor based on oxidative stress and mitochondrial dysfunction-related genes

  2023cites this paper
• Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers

  2023cites this paper
• Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights

  2023cites this paper
• The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma.

  2023cites this paper
• Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy.

  2023cites this paper
• Pancreatic Organoids: A Frontier Method for Investigating Pancreatic-Related Diseases

  2023cites this paper
• Holistic Understanding of the Role of Carbohydrate Antigen 19-9 in Pancreatic Cancer Screening, Early Diagnosis, and Prognosis: A Systematic Review

  2023cites this paper
• Recent Advances in CAR-Based Solid Tumor Immunotherapy

  2023cites this paper
• The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook

  2023cites this paper
• Advancing Cancer Treatment Through Nanotechnology Driven Immunotherapy for Pancreatic Cancer

  2023cites this paper
• Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models

  2023cites this paper
• Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.

  2023cites this paper
• Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought

  2022cites this paper
• Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes

  2022cites this paper
• Comprehensive characterization of extracellular matrix-related genes in PAAD identified a novel prognostic panel related to clinical outcomes and immune microenvironment: A silico analysis with in vivo and vitro validation

  2022cites this paper
• Multiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy

  2022cites this paper
• Immunity and Pancreatic Cancer

  2022cites this paper
• Combination immunotherapy for pancreatic cancer: challenges and future considerations

  2022influential citation
• Locoregional Delivery of CAR-T Cells in the Clinic.

  2022cites this paper
• Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives

  2022cites this paper
• Advancing together and moving forward: Combination gene and cellular immunotherapies

  2022cites this paper
• The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma

  2022cites this paper
• Progress and prospects for use of cellular immunotherapy in pancreatic cancer

  2022cites this paper